在印度背景下重新定位磺脲类药物用于2型糖尿病管理的时机：一种务实的实用方法。
Time to reposition sulfonylureas in type 2 diabetes management in Indian context: A pragmatic practical approach.
作者信息
Das Ashok Kumar, Saboo Banshi, Chawla Rajeev, Aravind S R, Rajput Rajesh, Singh Awadhesh K, Mukherjee J J, Jhingan Ashok, Shah Parag, Deshmukh Vaishali, Kale Shailaja, Jaggi Shalini, Sridhar G R, Dhediya Rajnish, Gaurav Kumar
机构信息
Department of Endocrinology and Medicine, Pondicherry Institute of Medical Sciences, Puducherry, India.
Department of Diabetology, DIA-CARE, Ahmedabad, India.
出版信息
Int J Diabetes Dev Ctries. 2023 Apr 19:1-19. doi: 10.1007/s13410-023-01192-6.
Sulfonylureas (SU) continue to be a vital therapeutic category of oral hypoglycemic agents (OHAs) for the management of type 2 diabetes mellitus (T2DM). Physicians consider modern SU (gliclazide and glimepiride) as "safe and smart" choices for T2DM management. The presence of multiple international guidelines and scarcity of a national guideline may contribute to the challenges faced by few physicians in choosing the right therapeutic strategy. The role of SU in diabetes management is explicit, and the present consensus aims to emphasize the benefits and reposition SU in India. This pragmatic, practical approach aims to define expert recommendations for the physicians to improve caregivers' knowledge of the management of T2DM, leading to superior patient outcomes.
磺脲类药物（SU）仍然是用于治疗2型糖尿病（T2DM）的重要口服降糖药物类别。医生认为现代磺脲类药物（格列齐特和格列美脲）是治疗T2DM的“安全且明智”的选择。多个国际指南的存在以及国家指南的缺乏，可能导致少数医生在选择正确治疗策略时面临挑战。SU在糖尿病管理中的作用是明确的，目前的共识旨在强调其益处并在印度重新定位SU。这种务实、实用的方法旨在为医生确定专家建议，以提高护理人员对T2DM管理的认识，从而带来更好的患者治疗效果。
Zotero 插件